Interferon-α treatment of patients with hepatitis C: The role of a comprehensive risk-benefit assessment (multiple letters)

Muhamad Aly Rifai; Jennifer M. Loftis; Peter Hauser; Charles L. Raison; Marina Demetrashvili; Lucile Capuron; Andrew H. Miller

doi:10.2165/00023210-200519080-00009

Interferon-α treatment of patients with hepatitis C: The role of a comprehensive risk-benefit assessment (multiple letters)

Muhamad Aly Rifai, Jennifer M. Loftis, Peter Hauser, Charles L. Raison, Marina Demetrashvili, Lucile Capuron, Andrew H. Miller

Psychiatry

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	719-721
Number of pages	3
Journal	CNS Drugs
Volume	19
Issue number	8
DOIs	https://doi.org/10.2165/00023210-200519080-00009
State	Published - Jan 1 2005

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.2165/00023210-200519080-00009

Cite this

@article{cc4fd094cf98430c960a22dec93ab92a,

title = "Interferon-α treatment of patients with hepatitis C: The role of a comprehensive risk-benefit assessment (multiple letters)",

author = "Rifai, {Muhamad Aly} and Loftis, {Jennifer M.} and Peter Hauser and Raison, {Charles L.} and Marina Demetrashvili and Lucile Capuron and Miller, {Andrew H.}",

year = "2005",

month = jan,

day = "1",

doi = "10.2165/00023210-200519080-00009",

language = "English (US)",

volume = "19",

pages = "719--721",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Adis International Ltd",

number = "8",

}

TY - JOUR

T1 - Interferon-α treatment of patients with hepatitis C

T2 - The role of a comprehensive risk-benefit assessment (multiple letters)

AU - Rifai, Muhamad Aly

AU - Loftis, Jennifer M.

AU - Hauser, Peter

AU - Raison, Charles L.

AU - Demetrashvili, Marina

AU - Capuron, Lucile

AU - Miller, Andrew H.

PY - 2005/1/1

Y1 - 2005/1/1

UR - http://www.scopus.com/inward/record.url?scp=24144458304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144458304&partnerID=8YFLogxK

U2 - 10.2165/00023210-200519080-00009

DO - 10.2165/00023210-200519080-00009

M3 - Letter

C2 - 16097855

AN - SCOPUS:24144458304

SN - 1172-7047

VL - 19

SP - 719

EP - 721

JO - CNS Drugs

JF - CNS Drugs

IS - 8

ER -

Interferon-α treatment of patients with hepatitis C: The role of a comprehensive risk-benefit assessment (multiple letters)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this